CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionProfit margin is 84.2%, higher than 95% of its Biotechnology peers (median -47.7%)
- FinancialsAltman Z-Score 11.64: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
960.81MUSDvs all stocks (USD)
Trailing P/E
6.15xvs Biotechnology peers
Revenue (TTM)
181.72MUSDvs all stocks (USD)
Profit Margin
84.23%vs Biotechnology peers
Beta
0.6220xvs all stocks
52-Week Change
8.74%vs all stocks
Market Capitalization
960.81MUSDvs all stocks (USD)
Enterprise Value
876.50MUSDvs all stocks (USD)
Trailing P/E
6.15xvs Biotechnology peers
Forward P/E
-29.37xvs Biotechnology peers
PEG Ratio
-0.0154xvs Biotechnology peers
Price to Sales (TTM)
5.29xvs Biotechnology peers
Price to Book (MRQ)
3.71xvs Biotechnology peers
Enterprise to Revenue
4.82xvs Biotechnology peers
Enterprise to EBITDA
5.94xvs Biotechnology peers
Profit Margin
84.23%vs Biotechnology peers
Operating Margin
-567.16%vs Biotechnology peers
Return on Assets (TTM)
48.84%vs Biotechnology peers
Return on Equity (TTM)
89.58%vs Biotechnology peers
Revenue (TTM)
181.72MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.9370USDUpdated Sep 26, 2026Quarterly Revenue Growth
-90.60%vs Biotechnology peers
Gross Profit (TTM)
163.92MUSDvs all stocks (USD)
EBITDA (TTM)
147.47MUSDvs all stocks (USD)
Net Income (TTM)
153.05MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-90.56%vs Biotechnology peers
Operating Cash Flow (TTM)
-24.63MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-80.24MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
14.08MUSDFY2025 · Dec 31, 2025Operating Income
-27.05MUSDvs all stocks (USD)
Pre-tax Income
-33.50MUSDFY2025 · Dec 31, 2025Net Income
-33.50MUSDFY2025 · Dec 31, 2025EBIT
-33.40MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-22.62MUSDFY2025 · Dec 31, 2025Research & Development
25.24MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
15.89MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.07MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
97.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.1700USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.1700USDFY2025 · Dec 31, 2025Basic Shares Outstanding
191.60MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
191.60MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-33.50MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-39.02MUSDFY2025 · Dec 31, 2025Free Cash Flow
-39.38MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
18.01MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-33.50MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
363.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.95MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-3.22MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.38MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.99MUSDFY2025 · Dec 31, 2025Capital Expenditures
364.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-140.06MUSDFY2025 · Dec 31, 2025Sale of Investments
155.28MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
15.58MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
197.63MSharesUpdated Sep 26, 2026Float Shares
122.66MSharesUpdated Sep 26, 2026Shares Short
18.48MSharesUpdated Sep 26, 2026Short Ratio
3.66daysvs all stocks
Short % of Shares Outstanding
13.86%vs all stocks
% Held by Insiders
20.40%vs all stocks
% Held by Institutions
72.77%vs all stocks
Total Cash (MRQ)
92.63MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4680USDUpdated Sep 26, 2026Total Debt (MRQ)
3.63MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0140xvs Biotechnology peers
Current Ratio (MRQ)
81.42xvs Biotechnology peers
Book Value per Share (MRQ)
1.31USDUpdated Sep 26, 2026Total Assets
94.62MUSDvs all stocks (USD)
Total Current Assets
94.46MUSDFY2025 · Dec 31, 2025Total Liabilities
18.04MUSDFY2025 · Dec 31, 2025Total Non-current Assets
162.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
12.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
6.01MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
18.01MUSDFY2025 · Dec 31, 2025Other Short-term Investments
73.46MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.45MUSDFY2025 · Dec 31, 2025Accounts Payable
1.17MUSDFY2025 · Dec 31, 2025Short-term Debt
547.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
640.00KUSDFY2025 · Dec 31, 2025Long-term Debt
199.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
11.84MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.42BUSDFY2025 · Dec 31, 2025Retained Earnings
-1.38BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
76.58MUSDvs all stocks (USD)
52-Week Low
3.50USDUpdated Sep 26, 202652-Week High
5.45USDUpdated Sep 26, 202652-Week Change
8.74%vs all stocks
Beta
0.6220xvs all stocks
50-Day MA
4.81USDUpdated Sep 26, 2026200-Day MA
4.54USDUpdated Sep 26, 2026Avg 10-Day Volume
5.32MSharesUpdated Sep 26, 2026Avg 30-Day Volume
5.10MSharesUpdated Sep 26, 2026Diluted EPS (TTM)
0.7900USDUpdated Sep 26, 2026Other Income / Expense
-10.42MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 84.2%, higher than 95% of its Biotechnology peers (median -47.7%)Significant
Profit margin: 0.84Industry median: -0.48Industry P95: 0.42Peers compared: 260
Return on equity is 89.6%, higher than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: 0.90Industry median: -0.22Industry P95: 0.23Peers compared: 260
Return on assets is 48.8%, higher than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: 0.49Industry median: -0.20Industry P95: 0.15Peers compared: 260
Current ratio is 81.42×, higher than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 81.42Industry median: 5.71Industry P95: 22.21Peers compared: 260
P/E ratio is 6.15×, lower than 95% of its Biotechnology peers (median 32.17×)Notable
P/E ratio: 6.15Industry median: 32.17Industry P5: 6.16Peers compared: 260
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 153,054,000Operating Cash Flow (USD, TTM): -24,625,000
Financial Health
Altman Z-Score 11.64: safe zoneNotable
Altman Z-Score: 11.64
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Cullinan Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pharma Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Corvus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anhui Tatfook Technology Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Hebei Sailhero Environmental Protection Hi-Tech Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Finolex Industries Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity